Our findings, along with previous studies of ELF1 and its subfamily, suggest that ELF1 has the ability to compete with other expressed ETS factors and is also able to regulate cell fate decisions in prostate cancer cells. The gene discussed is ELF1; the disease is prostate carcinoma.